Invention Grant
- Patent Title: Use of ureidomustine (BO-1055) in cancer treatment
-
Application No.: US15745639Application Date: 2016-08-17
-
Publication No.: US10548861B2Publication Date: 2020-02-04
- Inventor: Malcolm Moore , Jae-Hung Shieh , Tsann-Long Su , Te-Chang Lee
- Applicant: Academia Sinica , Memorial Sloan Kettering Cancer Center
- Applicant Address: TW Nankang, Taipei US NY New York
- Assignee: Academia Sinica,Memorial Sloan Kettering Cancer Center
- Current Assignee: Academia Sinica,Memorial Sloan Kettering Cancer Center
- Current Assignee Address: TW Nankang, Taipei US NY New York
- Agency: Wood, Phillips, Katz, Clark & Mortimer
- International Application: PCT/US2016/047264 WO 20160817
- International Announcement: WO2017/031156 WO 20170223
- Main IPC: A61K31/167
- IPC: A61K31/167 ; A61K31/17 ; A61K45/06 ; A61P35/02
Abstract:
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.
Public/Granted literature
- US20190008808A1 Use of Ureidomustine (BO-1055) in Cancer Treatment Public/Granted day:2019-01-10
Information query
